Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review
- PMID: 33514495
- DOI: 10.1016/j.jmii.2021.01.001
Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review
Abstract
Because of the high incidence of cytomegalovirus (CMV) seropositivity in the population, CMV infection is a common and severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Taiwan. Here we propose a CMV management strategy for patients undergoing allo-HSCT from the Taiwanese perspective, which focuses on the epidemiology, diagnosis, monitoring, prophylaxis, and treatment of CMV infection after allo-HSCT. In terms of CMV monitoring, weekly CMV monitoring with the COBAS® AmpliPrep system is the standard approach because the pp65 CMV antigenemia assay has a lower sensitivity than CMV monitoring with the COBAS® AmpliPrep system. However, pp65 CMV antigenemia assay has a better correlation with clinical symptoms in immunocompromised patients. A 14-week prophylactic course of letermovir is recommended for allo-HSCT recipients in Taiwan, especially for recipients of hematopoietic stem cells from mismatched unrelated and haploidentical donors. Preemptive ganciclovir therapy should be initiated when the CMV viral load exceeds 1000 copies/mL, and should not be discontinued until CMV DNA is no longer detected in the blood. For allo-HSCT recipients who have CMV-related diseases, ganciclovir with or without CMV-specific intravenous immunoglobulin is the standard of care. The limited availability of foscarnet, an alternative for patients who are not responsive to or cannot tolerate ganciclovir, is a crucial issue in Taiwan. For pediatric allo-HSCT recipients, more data are needed to propose a CMV management recommendation.
Keywords: Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Ganciclovir; Preemptive; Prophylaxis.
Copyright © 2021. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest Chieh-Lin Jerry Teng received an honorarium and consulting fees from Novartis, Roche, Takeda, Johnson & Johnson, Amgen, BMS Celgene, Kirin, and MSD. The other authors declare that they have no conflicts of interest.
Similar articles
-
[Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].Zhonghua Nei Ke Za Zhi. 2018 Mar 1;57(3):191-195. doi: 10.3760/cma.j.issn.0578-1426.2018.03.008. Zhonghua Nei Ke Za Zhi. 2018. PMID: 29518863 Chinese.
-
Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.Transpl Infect Dis. 2016 Jun;18(3):396-404. doi: 10.1111/tid.12539. Epub 2016 Jun 9. Transpl Infect Dis. 2016. PMID: 27041364
-
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2001;7(6):343-51. doi: 10.1016/s1083-8791(01)80005-7. Biol Blood Marrow Transplant. 2001. PMID: 11464977 Clinical Trial.
-
Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.Int J Hematol. 2010 May;91(4):588-95. doi: 10.1007/s12185-010-0569-x. Epub 2010 Apr 23. Int J Hematol. 2010. PMID: 20414753 Review.
-
Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients.Expert Rev Clin Immunol. 2023 Feb;19(2):227-235. doi: 10.1080/1744666X.2023.2161510. Epub 2023 Jan 1. Expert Rev Clin Immunol. 2023. PMID: 36541485 Review.
Cited by
-
Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea.PLoS One. 2023 Sep 13;18(9):e0291268. doi: 10.1371/journal.pone.0291268. eCollection 2023. PLoS One. 2023. PMID: 37703263 Free PMC article.
-
The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder.J Clin Med. 2022 Sep 1;11(17):5187. doi: 10.3390/jcm11175187. J Clin Med. 2022. PMID: 36079123 Free PMC article.
-
Advances and Challenges in Cytomegalovirus Detection Methods for Liver Transplant Donors.Diagnostics (Basel). 2023 Oct 26;13(21):3310. doi: 10.3390/diagnostics13213310. Diagnostics (Basel). 2023. PMID: 37958206 Free PMC article. Review.
-
CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.Bone Marrow Transplant. 2023 Jun;58(6):639-646. doi: 10.1038/s41409-023-01944-2. Epub 2023 Mar 3. Bone Marrow Transplant. 2023. PMID: 36869190 Free PMC article.
-
Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes.Bone Marrow Transplant. 2022 Sep;57(9):1411-1420. doi: 10.1038/s41409-022-01744-0. Epub 2022 Jun 25. Bone Marrow Transplant. 2022. PMID: 35752740
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical